智通财经APP获悉，2月10日，强生(JNJ.US)宣布，美国FDA已授予在研抗体疗法nipocalimab突破性疗法认定，用于治疗有高风险出现严重新生儿溶血病(HDFN)的孕妇。如果获得批准，nipocalimab将成为首款治疗这一患者群体的获批疗法。 据了解，Nipocalimab是一款潜在“best-in-class”，靶向新生儿Fc受体(FcRn)的抗体疗法。它通过与FcRn结合，让被单核细胞和内皮细胞摄入的自身抗体不会被重新释放到血液中，而是在细胞内被降解。已有研究显示，它可以将血液循环中包括致病自身抗体在内的IgG水平降低超过75%。这款抗体疗法有望治疗多种自身抗体介导的免疫疾病。 突破性疗法认定的授予是基于开放标签2期临床试验UNITY的试验结果。这项临床试验达到主要终点。试验结果显示，接受治疗的13名参与者中12名成功生产。54%的孕妇在孕期32周之后，不需要宫腔内输血可成功生下婴儿。这一比例显著高于历史研究的参考值(10%)。在达到主要终点的7名孕妇中，中位孕期为37周零一天。 ...

domin_domin This article was coproduced with Chuck Walston. With the spinoff of its consumer-health segment, now known as Kenvue (KVUE), Johnson & Johnson (NYSE:JNJ) is now focused on its pharmaceuticals and medical devices businesses. Pharmaceuticals now generate just under two-thirds of the company’s revenue, with the latter segment hauling in the remainder. With a solid pipeline of cancer, immunology, and neurology drugs, along with a market leading medical device portfolio, management believes JNJ o ...

Income-oriented investors often look to dividend stocks to generate a reliable cash flow stream. However, not all dividend payers are created equal. The most dependable dividend stocks belong to an elite group known as the Dividend Aristocrats. These are S&P 500 companies that have increased their dividends annually for at least 25 consecutive years. This remarkable track record demonstrates financial stability and a consistent commitment to rewarding shareholders.Dividend stocks offer many appealing benefi ...

Kenvue Inc.’s stock KVUE, -0.39% fell by 3.2% in premarket trading on Thursday after the household products spin-off of Johnson & Johnson JNJ, -0.05% reported lower fourth-quarter profit and said its 2024 earnings would fall short of the FactSet consensus estimate. It also missed its revenue target for the fourth quarter. Kenvue said its net income for the three months ended Dec. 31 fell to $327 million, or 17 cents a share, from $361 million, or 21 cents a share, in the year-ago quarter. Adjusted fourth-q ...

Johnson & Johnson (JNJ -0.05%) has a lot going for it in the eyes of investors. The company's pharmaceutical sales are growing due to recently launched blockbuster drugs. Lately, its medical technology business is growing faster than pharmaceutical sales, thanks to a rush of seniors who need to replace their knees and hips.Warren Buffett doesn't seem too thrilled with the stock, even though the company has a pair of business segments that keep moving in the right direction. Last year, Berkshire Hathaway, th ...

Johnson & Johnson (JNJ 1.45%) is one of the world's most recognized healthcare brands. Ironically, the consumer products like Band-Aids and Tylenol that consumers know it for are technically no longer part of the company after their spinoff as Kenvue.Today, Johnson & Johnson is a two-headed monster focused on pharmaceutical and medical device innovations. The stock drifted for much of the past year despite the company's strong operating results.It's unclear how long this will last, making the company a rare ...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Raymond James 45th Annual Institutional Investors Conference on Tuesday, March 5th, at the JW Marriott Orlando Grande Lakes, Orlando, FL. Ahmet Tezel, Company Group Chairman, MedTech R&D will represent the Company in a session scheduled at 2:15 p.m. (Eastern Time). This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com. ...

Patience has proven invaluable to long-term investors, with every stock market correction, crash, and bear market eventually put into the rearview mirror by a bull market rally. But over shorter periods, Wall Street's benchmark index, the S&P 500 (^GSPC 0.76%), has proved unpredictable.In successive years since this decade began, the S&P 500 has bounced between bear and bull markets. Although some investors define a bull market as one which has rallied at least 20% from a recent low, there's little question ...

In this articleMRKBMYJNJThe New York Stock Exchange welcomes Johnson & Johnson (NYSE: JNJ) to the podium. NYSEBig pharmaceutical companies such as Bristol Myers Squibb, Merck and Johnson & Johnson face a looming threat that will put tens of billions of dollars in sales at risk between now and 2030, as blockbuster drugs will tumble off a so-called patent cliff.That refers to when a company's patents for one or more leading branded products expire, which opens the door for competitors to sell copycats of thos ...

Mario Tama/Getty Images News Thesis Johnson & Johnson (NYSE:JNJ) is a multinational corporation that operates in the healthcare and pharmaceutical sectors. Founded in 1886, the company is headquartered in New Brunswick, New Jersey, USA. JNJ is one of the largest and most diversified healthcare companies globally. Having experienced a dip in terms of its profitability and liquidity in recent years, the pharma giant has been showing indications of a major acceleration in growth with their heavy focus on t ...